Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 12/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9662514 | 0.88 | PTGS2 (0.54) | GPR17KDM4E | |
| SCHEMBL9186531 | 0.84 | GPR17 (1.00) | GPR17KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL14739421 | 0.81 | GPR17 (1.00) | GPR17KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL9189908 | 0.81 | GPR17 (0.66) | GPR17KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL9189877 | 0.79 | GPR17 (0.81) | GPR17KDM4EALDH1A1 | |
| SCHEMBL31025911 | 0.79 | KIF11 (0.52) | GPR17KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2494500 | 0.79 | EIF4A3 (0.55) | GPR17KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL9661003 | 0.79 | GPR17 (0.48) | GPR17ALDH1A1HSD17B10 | |
| SCHEMBL9188978 | 0.78 | GPR17 (0.72) | GPR17KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL9188883 | 0.77 | GPR17 (0.71) | GPR17KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4960786-A | Excitatory amino acid antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-10-02 | — | — | US | claimed |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| CN-111386107-A | Use of probenecid in the treatment of an epileptic disease, disorder or condition | 巴黎科技与文学─拉丁区 | 2020-07-07 | — | — | CN | disclosed |
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-3651758-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019012109-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2019-01-17 | — | — | WO | disclosed |
| EP-0394905-B1 | Excitatory amino acid antagonists | MERRELL DOW PHARMA (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0394905-A2 | Excitatory amino acid antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4960786-A | Excitatory amino acid antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | GPR17 1618/4885KDM4E 4411/4885ALDH1A1 528/4885 |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | GPR17 1618/4885KDM4E 4411/4885ALDH1A1 528/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | GPR17 1618/4885KDM4E 4411/4885ALDH1A1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.